HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BAO PHARMA-B

16.440

+0.6203.92%

Volume:1.07M

Turnover:17.47M

Market Cap:5.33B

PE:-10.36

High:16.800

Open:15.850

Low:15.380

Close:15.820

52wk High:206.000

52wk Low:15.300

Shares:324.00M

HK Float Shares:153.00M

Volume Ratio:5.42

T/O Rate:0.70%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.586

ROE:-31.30%

ROA:-10.95%

PB:3.15

PE(LYR):-10.36

PS:267.99

Loading ...

Overview Company News Filings

Bao Pharma’s Human Hyaluronidase Injection Receives NMPA Marketing Approval

Bulletin Express

BAO PHARMA-B (02659) Receives NMPA Approval for Recombinant Human Hyaluronidase Injection

Shanghai Bao says NMPA approves human hyaluronidase injection for marketing

Shanghai Bao Pharmaceuticals - Nmpa Approves Human Hyaluronidase for Injection (Kj017) for Marketing

THOMSON REUTERS

Bao Pharma Maintains Stable Share Capital in March 2026, Reaffirms Public-Float Compliance

Bulletin Express

BAO PHARMA-B Shares Surge Over 8% in Late Trading as SJ02 Commercialization Begins and KJ103 NDA Submission Expected

BRIEF-Shanghai Bao Pharmaceuticals Proposes To Elect Liu Yanjun, Wang Zheng, Li Cui As Executive Directors

Bao Pharma Proposes Full Board Re-election and Articles Revision to Align with China’s New Company Law

Bulletin Express

BAO PHARMA-B Reports 2025 Results: Core Pipeline Advances Rapidly, SJ02 Completes Initial Order Delivery

Shanghai Bao Pharmaceuticals - Proposes to Elect Liu Yanjun, Wang Zheng, Li Cui as Executive Directors

THOMSON REUTERS

Shanghai Bao Pharmaceuticals Co Ltd - FY Revenue RMB49.2 Mln

THOMSON REUTERS

Shanghai Bao Pharmaceuticals FY2025 revenue jumps to RMB49 million; operating loss widens to RMB395 million

BAO PHARMA-B (02659) Concludes Phase III Trial Follow-Up for KJ103 in Kidney Transplant Desensitization

Shanghai Bao Pharma completes Phase III trial follow-up for first-in-class KJ103 in kidney-transplant desensitisation

Bulletin Express

Shanghai Bao shares rise; KJ103 Phase III kidney transplant desensitization trial follow-up completed, NDA filing planned with China’s NMPA

Shanghai Bao shares rise; KJ103 Phase III kidney transplant desensitization trial completes primary follow-up, NDA submission planned with China NMPA

BAO PHARMA-B (02659) schedules 26 Mar 2026 board meeting to approve FY2025 annual results

Bulletin Express

Shanghai Bao Pharmaceuticals schedules board meeting to approve FY2025 annual results

BAO PHARMA-B Receives Approval for Additional Clinical Trial of KJ101

Bao Pharma-B (02659) Receives NMPA Approval to Launch Clinical Trial of KJ101 for Gastric Mucus Removal

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/02659/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02659","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02659\",,,,,undefined,":{"symbol":"02659","market":"HK","secType":"STK","nameCN":"BAO PHARMA-B","latestPrice":16.44,"timestamp":1788163726530,"preClose":15.82,"halted":0,"volume":1069213,"delay":0,"changeRate":0.03919089759797731,"floatShares":153000000,"shares":324000000,"eps":-1.586261581150355,"marketStatus":"Closed","change":0.62,"latestTime":"08-31 16:08:46","open":15.85,"high":16.8,"low":15.38,"amount":17469860,"amplitude":0.08976,"askPrice":16.67,"askSize":1200,"bidPrice":16.44,"bidSize":2200,"shortable":0,"etf":0,"ttmEps":-1.373611552509053,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":5,"adr":0,"listingDate":1765296000000,"exchange":"SEHK","adjPreClose":15.82,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"volumeRatio":5.418675,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02659\",,,,,undefined,":{"symbol":"02659","floatShares":153000000,"roa":"-10.95%","roe":"-31.30%","lyrEps":-1.586262,"volumeRatio":5.418675,"shares":324000000,"dividePrice":0,"high":16.8,"amplitude":0.08976,"preClose":15.82,"low":15.38,"week52Low":15.3,"pbRate":"3.15","psRate":"267.99","week52High":206,"institutionHeld":0,"latestPrice":16.44,"committee":0.294118,"eps":-1.586261581150355,"divideRate":0,"volume":1069213,"delay":0,"ttmEps":-1.373611552509053,"open":15.85,"prevYearClose":77.55,"prevWeekClose":15.82,"prevMonthClose":17.25,"prevQuarterClose":18,"fiveDayClose":15.73,"twentyDayClose":17.13,"sixtyDayClose":22.56},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02659\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"02659","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787880600000,"name":null,"time":"","dateTimestamp":1787846400000,"actualEps":null},{"date":"2026-03-26","symbol":"02659","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774488600000,"name":null,"time":"","dateTimestamp":1774454400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02659\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02659\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1779984000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02659\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02659","date":"2026-08-28","current":-11.724854,"percent":0.994253,"low":-150.791275,"twenty":-75.047246,"median":-53.651638,"eighty":-12.841314,"high":-11.128507,"avg":-47.396445,"sd":35.818109,"marketCap":5157026776},"quantilePoints":[{"date":"2025-12-12","current":-53.146224,"twenty":-53.348389,"median":-51.086695,"eighty":-37.627242,"marketCap":22280833132},{"date":"2025-12-19","current":-56.628418,"twenty":-56.115318,"median":-53.146224,"eighty":-50.330094,"marketCap":23796646945},{"date":"2025-12-24","current":-60.667186,"twenty":-57.368285,"median":-54.841733,"eighty":-51.357726,"marketCap":25573245929},{"date":"2026-01-02","current":-53.689307,"twenty":-58.867149,"median":-56.13619,"eighty":-51.993778,"marketCap":22720908110},{"date":"2026-01-09","current":-60.663453,"twenty":-59.744205,"median":-56.240552,"eighty":-53.146224,"marketCap":25736236661},{"date":"2026-01-16","current":-77.814349,"twenty":-61.547088,"median":-57.565784,"eighty":-53.651638,"marketCap":33119716844},{"date":"2026-01-23","current":-76.125836,"twenty":-72.759479,"median":-58.867149,"eighty":-53.689307,"marketCap":32369959474},{"date":"2026-01-30","current":-79.366151,"twenty":-76.125836,"median":-60.665319,"eighty":-55.0155,"marketCap":33902072360},{"date":"2026-02-06","current":-84.493791,"twenty":-76.125836,"median":-61.547088,"eighty":-55.626475,"marketCap":36183942615},{"date":"2026-02-13","current":-126.016863,"twenty":-78.017279,"median":-67.830536,"eighty":-56.031828,"marketCap":54275913922},{"date":"2026-02-20","current":-138.174242,"twenty":-79.686668,"median":-71.167377,"eighty":-56.115318,"marketCap":59426421069},{"date":"2026-02-27","current":-116.132786,"twenty":-104.714701,"median":-73.426035,"eighty":-56.395698,"marketCap":50494528928},{"date":"2026-03-06","current":-76.640212,"twenty":-111.983375,"median":-74.892856,"eighty":-56.998352,"marketCap":33054520551},{"date":"2026-03-13","current":-75.987902,"twenty":-110.582832,"median":-75.36732,"eighty":-57.563278,"marketCap":32924127965},{"date":"2026-03-20","current":-70.725897,"twenty":-109.509649,"median":-74.892856,"eighty":-57.733099,"marketCap":30528164197},{"date":"2026-03-27","current":-65.400661,"twenty":-104.714701,"median":-74.674242,"eighty":-58.326024,"marketCap":29273135557},{"date":"2026-04-02","current":-74.510382,"twenty":-96.653813,"median":-73.605533,"eighty":-59.04256,"marketCap":33510894602},{"date":"2026-04-10","current":-71.602503,"twenty":-91.308972,"median":-74.057958,"eighty":-59.568794,"marketCap":32451454840},{"date":"2026-04-17","current":-64.454748,"twenty":-86.399914,"median":-73.087213,"eighty":-60.479603,"marketCap":29224238337},{"date":"2026-04-24","current":-55.967849,"twenty":-84.718643,"median":-71.1642,"eighty":-60.173931,"marketCap":25377657050},{"date":"2026-04-30","current":-18.543355,"twenty":-83.426575,"median":-70.300184,"eighty":-58.506399,"marketCap":8410321797},{"date":"2026-05-08","current":-19.625214,"twenty":-81.092081,"median":-69.74185,"eighty":-56.760202,"marketCap":8931892141},{"date":"2026-05-15","current":-17.930681,"twenty":-79.944236,"median":-68.961959,"eighty":-55.831299,"marketCap":8182134771},{"date":"2026-05-22","current":-17.55647,"twenty":-79.579829,"median":-66.237091,"eighty":-53.674239,"marketCap":7993065521},{"date":"2026-05-29","current":-17.509903,"twenty":-78.962132,"median":-66.085797,"eighty":-51.516739,"marketCap":7999585151},{"date":"2026-06-05","current":-15.389804,"twenty":-78.220574,"median":-65.202887,"eighty":-19.743808,"marketCap":7041199644},{"date":"2026-06-12","current":-13.774642,"twenty":-77.936107,"median":-64.592987,"eighty":-19.178821,"marketCap":6297961903},{"date":"2026-06-18","current":-12.785133,"twenty":-77.726882,"median":-64.454748,"eighty":-18.7468,"marketCap":5857886926},{"date":"2026-06-26","current":-11.736313,"twenty":-77.358698,"median":-62.675612,"eighty":-18.25553,"marketCap":5352615655},{"date":"2026-07-03","current":-13.348826,"twenty":-77.285436,"median":-61.290684,"eighty":-17.828553,"marketCap":6092593580},{"date":"2026-07-10","current":-14.187594,"twenty":-77.122448,"median":-60.663453,"eighty":-17.509903,"marketCap":6467472265},{"date":"2026-07-17","current":-12.348746,"twenty":-76.777398,"median":-59.36056,"eighty":-15.389804,"marketCap":5649258788},{"date":"2026-07-24","current":-12.28898,"twenty":-76.640212,"median":-57.965274,"eighty":-14.102609,"marketCap":5623180271},{"date":"2026-07-31","current":-12.265678,"twenty":-76.228711,"median":-57.553252,"eighty":-13.925373,"marketCap":5623180271},{"date":"2026-08-07","current":-12.759971,"twenty":-76.015489,"median":-56.434485,"eighty":-13.758151,"marketCap":5861146740},{"date":"2026-08-14","current":-11.978357,"twenty":-75.491436,"median":-55.967849,"eighty":-13.50755,"marketCap":5509086758},{"date":"2026-08-21","current":-11.379099,"twenty":-75.31975,"median":-54.455852,"eighty":-13.139203,"marketCap":5245041771},{"date":"2026-08-28","current":-11.185615,"twenty":-75.047246,"median":-53.651638,"eighty":-12.841314,"marketCap":5157026776}],"updateTime":1788142198659},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02659\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1157149079","title":"Bao Pharma’s Human Hyaluronidase Injection Receives NMPA Marketing Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1157149079","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157149079?lang=en_us&edition=fundamental","pubTime":"2026-04-08 12:21","pubTimestamp":1775622096,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) announced that its internally developed product “Human Hyaluronidase for Injection” (brand name: 葆舒宜®, project code: KJ017) in the 385U/vial dosage...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169775980","title":"BAO PHARMA-B (02659) Receives NMPA Approval for Recombinant Human Hyaluronidase Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1169775980","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169775980?lang=en_us&edition=fundamental","pubTime":"2026-04-08 12:10","pubTimestamp":1775621418,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B (02659) announced that on March 31, 2026, its self-developed, leading recombinant human hyaluronidase injection (Baoshuyi®, project code KJ017), with a specification of 385U per vial,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","IPOS","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625991606","title":"Shanghai Bao says NMPA approves human hyaluronidase injection for marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2625991606","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625991606?lang=en_us&edition=fundamental","pubTime":"2026-04-08 12:01","pubTimestamp":1775620893,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals won China NMPA marketing clearance for KJ017 human hyaluronidase for injection.Approval covers 385U/vial dose for use as adjuvant to subcutaneous infusion, including saline and lactated Ringer’s solutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bao Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL421Bbh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625991644","title":"Shanghai Bao Pharmaceuticals - Nmpa Approves Human Hyaluronidase for Injection (Kj017) for Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2625991644","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625991644?lang=en_us&edition=fundamental","pubTime":"2026-04-08 12:00","pubTimestamp":1775620848,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40Q1C4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164470710","title":"Bao Pharma Maintains Stable Share Capital in March 2026, Reaffirms Public-Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1164470710","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164470710?lang=en_us&edition=fundamental","pubTime":"2026-04-02 16:45","pubTimestamp":1775119505,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) filed its monthly return for the period ended 31 March 2026, showing no movement in either authorised or issued share capital. • Capital structure...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167543547","title":"BAO PHARMA-B Shares Surge Over 8% in Late Trading as SJ02 Commercialization Begins and KJ103 NDA Submission Expected","url":"https://stock-news.laohu8.com/highlight/detail?id=1167543547","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167543547?lang=en_us&edition=fundamental","pubTime":"2026-04-01 16:00","pubTimestamp":1775030424,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B (02659) saw its shares rise more than 8% in late trading. At the time of writing, the stock was up 6.57%, trading at HK$97.3, with a turnover of HK$84.53 million. The movement follows...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4585","BK4588","02659","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622856289","title":"BRIEF-Shanghai Bao Pharmaceuticals Proposes To Elect Liu Yanjun, Wang Zheng, Li Cui As Executive Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2622856289","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622856289?lang=en_us&edition=fundamental","pubTime":"2026-03-26 18:29","pubTimestamp":1774520983,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Bao Pharmaceuticals Proposes To Elect Liu Yanjun, Wang Zheng, Li Cui As Executive DirectorsMarch 26  - Shanghai Bao Pharmaceuticals Co Ltd 2659.HK:PROPOSES TO ELECT LIU YANJUN, WANG ZHENG, LI CUI AS EXECUTIVE DIRECTORSFurther company coverage: 2659.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40D1AO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154057497","title":"Bao Pharma Proposes Full Board Re-election and Articles Revision to Align with China’s New Company Law","url":"https://stock-news.laohu8.com/highlight/detail?id=1154057497","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154057497?lang=en_us&edition=fundamental","pubTime":"2026-03-26 16:44","pubTimestamp":1774514642,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma, HKEX: 02659) has released its AGM agenda, centering on a comprehensive board refresh and a constitutional overhaul triggered by the July 2024...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176257395","title":"BAO PHARMA-B Reports 2025 Results: Core Pipeline Advances Rapidly, SJ02 Completes Initial Order Delivery","url":"https://stock-news.laohu8.com/highlight/detail?id=1176257395","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176257395?lang=en_us&edition=fundamental","pubTime":"2026-03-26 16:38","pubTimestamp":1774514322,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B (02659) has announced its full-year results for the period ending December 31, 2025. During the reporting period, the company achieved total revenue of RMB 49 million and continued to...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622837210","title":"Shanghai Bao Pharmaceuticals -  Proposes to Elect Liu Yanjun, Wang Zheng, Li Cui as Executive Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2622837210","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622837210?lang=en_us&edition=fundamental","pubTime":"2026-03-26 16:35","pubTimestamp":1774514154,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40D1AO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622167837","title":"Shanghai Bao Pharmaceuticals Co Ltd - FY Revenue RMB49.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2622167837","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622167837?lang=en_us&edition=fundamental","pubTime":"2026-03-26 16:31","pubTimestamp":1774513905,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E0C2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622837126","title":"Shanghai Bao Pharmaceuticals FY2025 revenue jumps to RMB49 million; operating loss widens to RMB395 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622837126","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622837126?lang=en_us&edition=fundamental","pubTime":"2026-03-26 16:31","pubTimestamp":1774513891,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals published an annual results announcement for the year ended Dec. 31, 2025, reporting revenue of RMB49.2 million and a loss for the year of RMB395.3 million.Revenue more than doubled to RMB49.2 million, driven mainly by RMB40.0 million of licensing revenue and RMB3.6 million from initial commercial sales of pharmaceutical products.R&D expenses fell 1% to RMB248.2 million, reflecting lower share-based payment expenses, partly offset by higher trial and testing expenses and staff costs.Administrative expenses decreased 2.8% to RMB104.6 million, which the company attributed mainly to reduced share-based payment expenses.Cash and cash equivalents rose to RMB1.24 billion and total equity increased to RMB1.59 billion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be int","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL6F9KCn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136288467","title":"BAO PHARMA-B (02659) Concludes Phase III Trial Follow-Up for KJ103 in Kidney Transplant Desensitization","url":"https://stock-news.laohu8.com/highlight/detail?id=1136288467","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136288467?lang=en_us&edition=fundamental","pubTime":"2026-03-25 13:24","pubTimestamp":1774416257,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B (02659) has announced the completion of primary trial follow-up for all participants in the Phase III clinical study of KJ103 as a desensitization therapy for highly sensitized patients...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161","III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130445319","title":"Shanghai Bao Pharma completes Phase III trial follow-up for first-in-class KJ103 in kidney-transplant desensitisation","url":"https://stock-news.laohu8.com/highlight/detail?id=1130445319","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130445319?lang=en_us&edition=fundamental","pubTime":"2026-03-25 12:41","pubTimestamp":1774413690,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (Shanghai Bao Pharma) announced the completion of primary follow-up for all patients enrolled in its Phase III clinical study (CTR20252973) of KJ103 as a...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622499440","title":"Shanghai Bao shares rise; KJ103 Phase III kidney transplant desensitization trial follow-up completed, NDA filing planned with China’s NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2622499440","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622499440?lang=en_us&edition=fundamental","pubTime":"2026-03-25 12:20","pubTimestamp":1774412448,"startTime":"0","endTime":"0","summary":"Shanghai Bao shares rise; KJ103 Phase III kidney transplant desensitization trial follow-up completed, NDA filing planned with China’s NMPA. Shanghai Bao said follow-up for all enrolled patients in its Phase 3 trial of KJ103 for kidney-transplant desensitization in highly sensitized patients in China has been completed.The company plans to submit a new drug application to China’s National Medical Products Administration, which could position KJ103 for potential commercialization in the transplant-support market.KJ103 has received breakthrough therapy designation in China for this indication, a regulatory status that can support a faster path to review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bao Pharmaceuticals Co. Ltd.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL9csCFg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622049942","title":"Shanghai Bao shares rise; KJ103 Phase III kidney transplant desensitization trial completes primary follow-up, NDA submission planned with China NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2622049942","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622049942?lang=en_us&edition=fundamental","pubTime":"2026-03-25 12:20","pubTimestamp":1774412444,"startTime":"0","endTime":"0","summary":"Shanghai Bao shares rise; KJ103 Phase III kidney transplant desensitization trial completes primary follow-up, NDA submission planned with China NMPA. Shanghai Bao Pharmaceuticals said the Phase III trial of KJ103 as desensitization therapy for highly sensitized patients awaiting kidney transplantation in China completed primary follow-up for all enrolled subjects.The company said it plans to submit a new drug application to China’s National Medical Products Administration.No clinical results were reported in the announcement, and no future presentation of results was specified.KJ103 is described as a recombinant IgG-degrading enzyme intended to clear pre-existing HLA antibodies and reduce the risk of hyperacute rejection.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as finan","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL4LKWsy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113827952","title":"BAO PHARMA-B (02659) schedules 26 Mar 2026 board meeting to approve FY2025 annual results","url":"https://stock-news.laohu8.com/highlight/detail?id=1113827952","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113827952?lang=en_us&edition=fundamental","pubTime":"2026-03-16 16:42","pubTimestamp":1773650538,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (BAO PHARMA-B, stock code: 02659) has announced that its board of directors will convene on 26 March 2026 in Shanghai. The primary agenda is to review and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619453509","title":"Shanghai Bao Pharmaceuticals schedules board meeting to approve FY2025 annual results","url":"https://stock-news.laohu8.com/highlight/detail?id=2619453509","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619453509?lang=en_us&edition=fundamental","pubTime":"2026-03-16 16:31","pubTimestamp":1773649899,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals will hold a board meeting on 26 March 2026 to consider and approve the group’s annual results for the year ended 31 December 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bao Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL6F32N4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150262699","title":"BAO PHARMA-B Receives Approval for Additional Clinical Trial of KJ101","url":"https://stock-news.laohu8.com/highlight/detail?id=1150262699","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150262699?lang=en_us&edition=fundamental","pubTime":"2026-03-12 12:25","pubTimestamp":1773289506,"startTime":"0","endTime":"0","summary":"BAO PHARMA-B (02659) has announced that its self-developed recombinant human chymotrypsin KJ101, a leading product in China developed through synthetic biology, has received approval from China's...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157341579","title":"Bao Pharma-B (02659) Receives NMPA Approval to Launch Clinical Trial of KJ101 for Gastric Mucus Removal","url":"https://stock-news.laohu8.com/highlight/detail?id=1157341579","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157341579?lang=en_us&edition=fundamental","pubTime":"2026-03-12 12:03","pubTimestamp":1773288201,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma-B, 02659) announced that the National Medical Products Administration (NMPA) has cleared the company to initiate clinical trials of KJ101—its...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":6,"totalSize":126,"code":"91000000","status":"200"}]}}